Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-01-17
2006-01-17
Kifle, Bruck (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
active
06987105
ABSTRACT:
A new method to synthesize the platelet-activating factor antagonist which is a derivative of thienotriazolodiazepene, tetrahydro-4,7,8,10 methyl-1(chloro-2 phenyl)-6 (methosy-4 phenyl carbamoyl)-9 pyrido[4,3-:4,5] thieno[3,2-f] triazolo-1,2,4 [4,3-α] diazepine-1,4] (1) is disclosed. The compound synethesized by this new method has been designated “LAU-8080” which has the same structure as the compound currently named in the literature as “BN-50730.” LAU-8080 was shown to prevent photoreceptor cell death, inhibit pathological neovascularization in the retina, and minimize the loss of neurons due to ischemic-reperfusion damage due to stroke. Thus LAU-8080 can be used to treat the retinal diseases of age-related macular degeneration, retinitis pigmentosa, and diabetic retinopathy. It can also be used to minimize the neuronal damage due to stroke.
REFERENCES:
patent: 5049559 (1991-09-01), Braquet et al.
patent: 5049560 (1991-09-01), Esanu et al.
patent: 5492906 (1996-02-01), Braquet et al.
patent: 0 369 810 (1990-05-01), None
patent: 2 779 652 (1999-12-01), None
Doly et al. (Ophthalmic Research (1993), 25(5), 314-18).
Doly et al. (Acta Ophthalmologica Scandinavica (1995), 73(2), 155-7).
Menerath et al. (Journal of Ocular Pharmacology and Therapeutics (1997), 13(1), 81-88).
Baker M.L. et al., “Differential effect of platelet-activating factor on adhesion molecule expression by astrocytes and microglia,” Abstract, Soc. Neurosci., vol. 22 (1996).
Bazan, H. et al., “Platelet-activating factor induces collagenase expression in corneal epithelial cells,” Proc. Natl Acad Sci, vol. 90, pp. 8678-8682 (1993).
Bazan, H. et al., “Platelet-activating factor induces cyclooxygenase-2 gene expression in corneal epithelium. Requirement of calcium in the signal transduction pathway,” Invest Ophthalmol & Vis Sci, vol. 38, No. 12, pp. 2492-2501 (1997).
Bazan N.G., “Bioactive lipid and neuronal plasticity in neurodegenerative diseases,” Abstract, 655th Meeting of Biochemical Society, University of Manchester, Manchester, England (1995).
Bazan, N.G., “Bioactive lipids and gene expression in neuronal plasticity,” Chapter 3,Molecular and Cellular Mechanisms of Neuronal plasticity,Ehrlich (ed), Plenum Press, NY, pp. 37-49 (1998).
Bazan, N.G. “Bioactive lipids in the modulation of excitatory amino acid neurotransmitter release and of gene expression,” Abstract, Satellite Meeting of 15th ISN, “Lipid Messengers in the Nerous System, ” Tokyo, Japan (1995).
Bazan, N.G., “Cell signaling and gene expression in photoreceptor survival,” Abstract, Ocular Cell and Molecular Biology Symposium, Keystone, CO (1999).
Bazan, N.G., “COX-2 and oxidative stress in ischemic brain injury and neurodegeneration,” Abstract, 5th IUBMB Conference on The Biochemistry of Health and Diseases, Jersalem, Israel (1998).
Bazan, N.G., “COX-2 in ischemic brain injury and in neurodegeneration,” Abstract, Second International Workshop on COX-2, Kapalua, Hawaii (1998).
Bazan, N.G., “COX-2 in synaptic plasticity and neurodegenerative diseases,” Abstract, First International Workshop on COX-2, New Orleans, LA (1997).
Bazan, N.G., “COX-2 in synaptic plasticity and neurodegenration,” Abstract, IBCs Industry Symposium on COX-2 Inhibitiors, San Diego, CA (1998).
Bazan, N.G., “Endogenous neuroprotection mechanisms and inflammatory signaling in stroke,” Abstract, Princeton Conference on Cerebrovascular Disease (1998).
Bazan, N.G., “Epileptogenesis: Significance of information flow, sprouting and neuronal damage,” Abstract, Merritt-Putnam, Lectures on Epilepsy, New Orleans, LA (1998).
Bazan, N.G., “Excitable membrane-derived injury mediators: Glutamate release and regulation of gene expression,” Abstract, XVth Washington International Spring Symposium, Neurodegenerative Diseases, 95, Molecular and Cellular Mechanisms, and Therapeutic Advances, Advances, Washington, DC (1995).
Bazan, N.G., “Inflammatory signaling pathways in pharmacology of cerebral ischemia,”Pharmacology of Cerebral Ischemia,J Krieglstein (ed.) Medpharm Scientific Publ, Stuttgart, pp. 173-180 (1996).
Bazan, N.G., “Inflammatory signaling pathways in phamacology of cerebral ischemia,”Pharmacology of Cerebral Ischemia,J Krieglstein (ed.) Medpharm Scientific Publ, Stuttgart, pp. 173-180 (1996).
Bazan, N.G., “Inflammatory signaling pathways in pharmacology of cerebral ischemia,” 6th International Symposium on Pharmacology of Cerebral Ischemia, Marburg, Germany (1996).
Bazan, N.G., “Injury messengers, transcription factors, and gene expression in status epilepticus,” Summary, Int'l Symposium on Status Epilepticus Mechanisms and Management, Santa Monica, CA (1997).
Bazan, N.G., “Lipid messengers and prostaglandin endoperoxide synthase-2 in neuronal cell death,”Primer on Cerebrovascular Diseases,Chapter 53, Welsh et al. (eds.), Academic Press, pp. 193-195 (1997).
Bazan, N.G., “Lipid messengers in synaptic signaling: significance in neuronal survival,” Abstract, Satellite of the Joint meeting of the 16th Biennial meeting of the International Society for Neurochemistry and the 28th Annual Meeting of the American Society for Neurochemistry, “Lipid Messengers in the Nervous System,” New Orleans, LA (1997).
Bazan, N.G., “Lipid-derived second messengers in the regulation of gene expression,” Abstract, The Advanced School of Neurochemistry 2nd Biennial Course on From Signal Transduction to Gene Expression, Okasaki, Japan (1995).
Bazan, N.G., “Neuronal cell signal transduction and gene expression in response to injury and experimental epilepsy,” Abstract, Fifth International Symposium MSNR 91, New Frontiers in the Biochemistry and Biophysics of Stroke, Neurotrauma and Other Neurological Disorders, Bristol, England (1991).
Braquet, p. et al., “New trends in PAF anatagonist research: A new series of potent hetrapazine-derived PAF antagonists,” Agents and Actions, vol. 32, pp. 34-36 (1991).
Campbell, F.Z. et al., “Excitatory amino acid neurotransmitter receptor agonist and platelet-activating factor (PAF) enhance the expression of the inducible proastagladin synthase-2 (COX-2) in primary hippocampal neurons,” Satellite of the meeting of the 16th Biennial meeting of the international Society for Neurochemistry and the 28th Annual Meeting of the American Society for Neurochemistry, “Lipid Messengers in the Nervous System,” New Orleans, LA (1997).
Decoster, M.A. et al., “Platelet-activating factor modulates intracellular calcium dynamics in rat hippocampai neurons,” Joint Meeting of the American Society for Biochemistry and Molecular Biology, Am. Soc. for Investigative Pathology, New Orleans, LA (1996).
DeCoster, M.A. et al., “Platelet-activating factor is a downstream messenger of kainate-induced activation of mitogen-activated protein kinases in primary hippocampal neurons,” J Neurosci Res. vol. 53, pp. 297-303 (1998).
de la Cruz, J.P. et al., “Effect of WEB 2086-BS, an antagonist of platelet-activating factor receptors, on retinal vascularity in diabetic rats,” European Journal of Pharmacology, vol. 360, pp. 37-42 (1998).
Doly, M. et al., “Prevention of chloroquine-induced electroretinographic damage by a new platelet-activating factor antagonist, BN 50730,” Opthalmic REs, vol. 25, pp. 314-318 (1993).
Doly, M. et al., “Protective effect of a specific PAF antagonist on vincristine-induced experimental retinopathy,” ACTA Opthalmologica Scandinavica, pp. 155-157 (1995).
Doucet, J.P., “Excitable membranes, lipid messengers, and immediate-early genes: Alteration of signal transduction in neurodulation and neurotrauma,” Mol Neurobiol, vol. 6, No. 4, pp. 407-424 (1992).
Doucet, J.P. et al., “Muscarinic inducti
Bazan Nicholas G.
Gomez Julio Alvarez Builla
Board of Supervisors of Louisiana State University And Agricultu
Davis Bonnie J.
Kifle Bruck
Runnels John H.
LandOfFree
Synthesis and use of thienotriazolodiazepines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Synthesis and use of thienotriazolodiazepines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Synthesis and use of thienotriazolodiazepines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3552050